Quick Answer
Crinetics Pharmaceuticals, Inc. reported Cash And Cash Equivalents At Carrying Value of $101.54 million for the year ending 2025.
- Crinetics Pharmaceuticals, Inc. showed a decrease of -61.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Crinetics Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $68.41 million | Q3 2018: $169.65 million | Q1 2019: $62.83 million | Q2 2019: $59.72 million | Q3 2019: $66.58 million | Q1 2020: $50.92 million | Q2 2020: $160.81 million | Q3 2020: $117.82 million | Q1 2021: $105.58 million | Q2 2021: $178.77 million | Q3 2021: $161.54 million | Q1 2022: $145.55 million | Q2 2022: $62.29 million | Q3 2022: $30.91 million | Q1 2023: $41.19 million | Q2 2023: $39.55 million | Q3 2023: $142.80 million | Q1 2024: $395.92 million | Q2 2024: $302.16 million | Q3 2024: $317.27 million | Q1 2025: $94.57 million | Q2 2025: $53.73 million | Q3 2025: $110.90 million.
- Over the full 9 years of available data (2017 to 2025), Crinetics Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 615.4%.
- Historical annual values: Fiscal year 2025: $101.54 million | Fiscal year 2024: $264.55 million | Fiscal year 2023: $54.90 million | Fiscal year 2022: $32.67 million | Fiscal year 2021: $200.70 million | Fiscal year 2020: $93.09 million | Fiscal year 2019: $40.33 million | Fiscal year 2018: $44.97 million | Fiscal year 2017: $14.19 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: